Five things for pharma marketers to know: Monday, February 13, 2016


1. Sanofi agreed to sell five over-the-counter products, including painkiller Prontalgine, to Ipsen for about $88 million. The deal emerged in the wake of the European Commission's requirement that Sanofi divest some assets in order to receive approval to acquire Boehringer Ingelheim's consumer health business. (Bloomberg)

2. Teva Pharmaceutical Industries reported 33% revenue growth, to $6.5 billion, in the fourth quarter. The surge was driven by the $40.5 billion acquisition of generic drug business Actavis in August. (Business Insider)

3. Regeneron Pharmaceutical received a subpoena regarding its support of nonprofit organizations that offer patients financial assistance. Federal agents are investigating other drugmakers running similar programs. (Stat)

4. Allergan said it will acquire Zeltiq Aesthetics for about $2.48 billion to gain access to its body-contouring technology. Zeltiq's CoolSculpting System is FDA-approved to reduce fat by cooling fat cells. (Reuters)

5. Agfa HealthCare, which provides healthcare IT and digital imaging solutions, is building an imaging platform with EHR integration. The platform comprises features such as storage layer, workflow and interface capabilities, and image-sharing. (Healthcare IT News)